Drug Profile
Anselamimab - Caelum Biosciences
Alternative Names: 11-1F4; CAEL-101; Ch mAb 11-1F4; Chimeric fibril reactive monoclonal antibody 11-1F4 -Caelum Biosciences; Fibril-reactive monoclonal antibody 11-1F4; mAb 11-1F4Latest Information Update: 22 Jan 2024
Price :
$50
*
At a glance
- Originator Columbia University
- Developer Alexion AstraZeneca Rare Disease; Caelum Biosciences
- Class Monoclonal antibodies
- Mechanism of Action Serum amyloid A protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase III Amyloid light-chain amyloidosis
Most Recent Events
- 09 Dec 2023 Adverse events data from phase II clinical trials in Amyloid light-chain amyloidosis were presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-2023)
- 14 Nov 2023 Alexion Pharmaceuticals completes a phase II trial in Amyloid light-chain amyloidosis (Combination therapy, Treatment-experienced) in USA (IV) (NCT04304144)
- 08 Jun 2023 Efficacy and adverse event data from a phase II/III trial in Amyloid light chain amyloidosis presented at 28th Congress of the European Haematology Association (EHA-2023)